Chairman of Global Vaccines – GSK
Dr.Slaoui is the chairman of Global Vaccines business since 2015 and headed the R & D for eight years before current role. A member of Corporate Executive Board & Board of Directors, he has been responsible for integration of Novartis Acquisition into Global vaccines business, Worldwide Business Development and External Alliances, franchise commercial organization, Bioelectronics R & D Strategy within GSK.
Dr.Slaoui is credited within GSK for overhauling its R&D and driving improvements in productivity, as well as shepherding its vaccines pipeline. He played an instrumental role in the recent formation of Galvani Bioelectronics (GSK & Alphabet Joint venture) and currently chairs Galvani`s board. Galvani is a crucial step in GSK`s Bioelectronics journey that combines tech & health for a new therapeutic modality and innovative precision medicines.
He has been a professor of Immunology at the University of Mons, Belgium. He has authored more than 100 scientific papers and presentations and is a member of the PhRMA Foundation Board of Directors, Advisory Board of Qatar Foundation, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors.
Dr.Slaoui earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.